Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors

Trial ID or NCT#

NCT01836549

Status

not recruiting iconNOT RECRUITING

Purpose

This molecular biology and phase II trial studies how well imetelstat sodium works in treating younger patients with recurrent or refractory brain tumors. Imetelstat sodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Official Title

A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma

Eligibility Criteria

Ages Eligible for Study: 12 Months to 21 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Paul Graham Fisher, MD
Paul Graham Fisher, MD
Neuro-oncologist, Pediatric neurologist
Beirne Family Professor of Pediatric Neuro-Oncology, Professor of Pediatrics and, by courtesy, of Neurosurgery and of Epidemiology and Population Health

Contact us to find out if this trial is right for you.

Contact

Pediatric Hematology/Oncology
650-723-5535